Forget Cannabis: Psychedelic Stocks Could Be the Next Big Thing for the Decade

Did you miss the epic cannabis rally in 2018? Don’t bother. These psychedelic stocks could be next up to break the roof.

Cannabis stocks made enormous wealth for its shareholders in 2018 and 2019 after being legalized in Canada. If you missed the rally, then the psychedelic stocks could be next up for a breakout.

Psychedelic stocks in 2020

Regulatory support and encouraging research outcomes sent these stocks through the roof late last year. To name a few, Numinus Wellness (TSXV:NUMI) is a Canada-based healthcare company that’s working around psychedelic therapies. NUMI soared a notable 510% last year. Another stock, Mind Medicine, surged a massive 860% in 2020.

In late 2019, the U.S. FDA (Food and Drug Administration) showed a ray of hope for the industry. It affirmed that psychedelic Psilocybin could be a breakthrough therapy for depression and mental disorders.

Psilocybin is a hallucinogenic compound generally found in a type of fungi that’s as popular as magic mushrooms. Studies have shown that this compound is effective in treating mental disorders, anxiety, depression, and addictions.

Strong growth prospects

According to research, the psychedelic industry is expected to grow to $6.85 billion by 2027. That’s more than 16% compounded annually from its current size. The growth potential is significantly large considering the globally rising depression and mental disorder cases.

Interestingly, regulators showed their support for the use of Psilocybin recently, which further boosted the industry sentiment. In November last year, Health Canada approved the therapeutic consumption of Psilocybin for patients with severe depression.

Oregon also became the first U.S. state to allow medical use of psychedelics last year. Industry experts are hopeful for more regulatory support going forward. If that happens, the industry growth will remarkably accelerate, and psychedelic stocks could soon skyrocket.

Looking to bet on psychedelic stocks?

Like biotech stocks, psychedelics are also extremely volatile. Numinus Wellness has been no different. It is the first company to receive a licence from Health Canada to produce and harvest magic mushrooms and extract and research Psilocybin. Numinus reported $229,188 in revenues for the quarter ended November 30, 2020, indicating 70% growth year over year. It is a loss-making company at the moment.

Though growth potential might look attractive, psychedelic stocks could be highly risky. Their smaller size and underlying uncertainties could make their volatility hard for investors’ appetite.

$1.2 billion Mind Medicine is a Canadian neuro-pharma company that’s working in this domain. It has several drugs in various stages of clinical trials. It is also working on developing a therapy using Psilocybin. The efficacy results of the subsequent trials will be interesting to see.

The first psychedelic-drug companies ETF began trading in Canada last week. The Horizons Psychedelic Fund is currently trading at $9.4 and tracks the North American Psychedelic Index. Some of the top holdings include Compass Pathways, Numinus Wellness, and Mind Medicine that forms 10%, 9%, and 9% in the fund, respectively. Johnson & Johnson is also a part with a 5% weighting.

Bottom line

Psychedelic drugs are an industry that is taking birth. The regulations and research around it will pave the way for it. The COVID-19 pandemic has substantially added to mental health problems, which should act as a catalyst for the industry.

Notably, psychedelics are prominently used for therapeutic purposes, and the recreational use seems very low, as of now. So, one can expect relatively faster approvals from regulators, unlike cannabis.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Vineet Kulkarni has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson.

More on Stocks for Beginners

A glass jar resting on its side with Canadian banknotes and change inside.
Stocks for Beginners

How to Grow Your TFSA Well Past the Average

Need to catch up quick with your TFSA? Consider some regular contributions to this top bank stock, as well as…

Read more »

An investor uses a tablet
Stocks for Beginners

Prediction: Here Are the Most Promising Canadian Stocks for 2025

Here are three top Canadian stocks that could deliver solid returns on your investments in 2025.

Read more »

Top TSX Stocks

A 6 Percent Dividend Yield Today! But Here’s Why I’m Buying This TSX Stock for the Long Term

Want a great stock to buy? You will regret not buying this TSX stock and its decades of growth and…

Read more »

grow money, wealth build
Dividend Stocks

TELUS Stock Has a Nice Yield, But This Dividend Stock Looks Safer

TELUS stock certainly has a shiny dividend, but the dividend stock simply doesn't look as stable as this other high-yielding…

Read more »

sale discount best price
Stocks for Beginners

Have $2,000? These 2 Stocks Could Be Bargain Buys for 2025 and Beyond

Fairfax Financial Holdings (TSX:FFH) and another bargain buy are fit for new Canadian investors.

Read more »

Rocket lift off through the clouds
Stocks for Beginners

2 Canadian Growth Stocks Set to Skyrocket in the Next 12 Months

Despite delivering disappointing performance in 2024, these two cheap Canadian growth stocks could offer massive upside in 2025.

Read more »

A train passes Morant's curve in Banff National Park in the Canadian Rockies.
Dividend Stocks

1 Magnificent Canadian Stock Down 12% to Buy and Hold Forever

This top stock may be down 12% right now, but don't see that as a problem. See it as a…

Read more »

woman looks at iPhone
Dividend Stocks

Retirees: Is TELUS Stock a Risky Buy?

TELUS stock has long been a strong dividend provider, but what should investors consider now after recent earnings?

Read more »